RELMADA THERAPEUTICS RLMD 深 沪
等待开盘 09-26 09:30:00 美东时间
1.66
+0.010
+0.61%
华盛通- 最 高1.68
- 今 开1.64
- 成交量 24.53万股
- 最 低 1.525
- 昨 收 1.65
- 总市值 5509.81万
- 52周最高 3.98
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 0.2404
- 委 比 -91.77%
- 总股本 3319.16万
- 历史最高 54.00
- 量 比 0.75
- 振 幅 9.39%
- 历史最低 0.2404
- 每 手 1
- 风险率 0.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Relmada Therapeutics Updates Corporate Presentation on NDV-01
Relmada Therapeutics ( ($RLMD) ) has shared an announcement. On September 17, 2...
09-17 19:59
Sidoti Events, LLC's Virtual September Small-Cap Conference
NEW YORK, NY / ACCESS Newswire / September 16, 2025 / Sidoti Events, LLC, an af...
09-16 23:20
Relmada regains Nasdaq compliance on minimum bid price
Relmada Therapeutics (NASDAQ:RLMD) on Tuesday said it has regained compliance with Nasdaq's $1.00 minimum bid price requirement. The company’s shares maintained a closing bid price of $1.00 or higher ...
09-16 22:19
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
Relmada Therapeutics, Inc. (NASDAQ: RLMD) announced on September 16, 2025, that it regained compliance with Nasdaq's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2) after maintaining a closing bid price of $1.00 for 10 consecutive business days. Nasdaq has closed the matter, and the Company remains fully compliant with all Nasdaq continued listing requirements. Relmada's shares will continue trading on the Nasdaq Capital Market ...
09-16 13:00
Relmada Therapeutics Highlights Strategic Progress to Shareholders
Relmada Therapeutics ( ($RLMD) ) has shared an update. On September 10, 2025, R...
09-10 21:19
Relmada Issues Mid-Year CEO Letter to Shareholders
<p>Relmada Therapeutics' CEO shares progress on their strategic review and portfolio expansion. NDV-01, a treatment for non-muscle invasive bladder cancer, shows strong Phase 2 results with a 91% complete response rate. The company is preparing for a Phase 3 trial in early 2026. They've also added sepranolone for Prader-Willi Syndrome, with Phase 2 plans set for mid-2026. Key experts Raj Pruthi, MD, and Yair Lotan, MD, have joined the team to sup...
09-10 11:15
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Relmada Therapeutics CMO Purchases 55,000 Shares
The latest update is out from Relmada Therapeutics ( ($RLMD) ). On August 29, 2...
09-02 19:59
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Relmada Therapeutics plans to host a conference call and webcast on August 7, 2025, at 4:30 PM ET to discuss second-quarter 2025 financial results and recent business progress. The call can be accessed via telephone (US: 1-877-407-0792; International: 1-201-689-8263; Conference ID: 13754263) or webcast link. A replay will be available on the company's website. Relmada is a clinical-stage biotech company developing therapies for oncology and CNS c...
07-31 11:00
